Steffen Nock
Stanford University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Steffen Nock.
FEBS Letters | 1997
Steffen Nock; James A. Spudich; Peter Wagner
A large variety of genes is expressed as fusion proteins for the purpose of characterization and purification in molecular biology. We have used this strategy to append polyarginine peptides in order to achieve specific binding of the Arg‐tag to atomically flat, negatively charged mica surfaces. We show that the model protein, hexaarginine‐tagged green fluorescent protein (GFP), binds to mica via its Arg‐tag based on ion exchange of naturally occurring potassium cations. Only non‐specific binding was observed with the control protein that is free of the Arg‐tag. This novel technology will be widely applicable to orient functional proteins on flat surfaces.
Proteome Science | 2003
Jens Sydor; Steffen Nock
The completion of the human genome sequence has led to a rapid increase in genetic information. The invention of DNA microarrays, which allow for the parallel measurement of thousands of genes on the level of mRNA, has enabled scientists to take a more global view of biological systems. Protein microarrays have a big potential to increase the throughput of proteomic research. Microarrays of antibodies can simultaneously measure the concentration of a multitude of target proteins in a very short period of time. The ability of protein microarrays to increase the quantity of data points in small biological samples on the protein level will have a major impact on basic biological research as well as on the discovery of new drug targets and diagnostic markers. This review highlights the current status of protein expression profiling arrays, their development, applications and limitations.
FEBS Letters | 2000
Steffen Nock; Wenchuan Liang; Hans M. Warrick; James A. Spudich
The dynamic assembly/disassembly of non‐muscle myosin II filaments is critical for the regulation of enzymatic activities and localization. Phosphorylation of three threonines, 1823, 1833 and 2029, in the tail of Dictyostelium discoideum myosin II has been implicated in control of myosin filament assembly. By systematically replacing the three threonines to aspartates, mimicking a phosphorylated residue, we found that position 1823 is the most critical one for the regulation of myosin filament formation and in vivo function. Surprisingly, a single charge change is able to perturb filament formation and in vivo function of myosin II.
Drug Discovery Today: Technologies | 2004
Krista Witte; Steffen Nock
The focus in the field of protein arrays has shifted from technology development to applying the technology in biological research. This review will highlight several recently published examples of biologically relevant experiments using both planar and bead-based arrays. Examples of the use of antibody arrays, antigen arrays and protein activity arrays will be discussed.:
PLOS ONE | 2016
Sarah L. Pogue; Tetsuya Taura; Mingying Bi; Yong Yun; Angela Sho; Glen Mikesell; Collette Behrens; Maya Sokolovsky; Hussein Hallak; Moti Rosenstock; Eric Sanchez; Haiming Chen; James R. Berenson; Anthony Gerard Doyle; Steffen Nock; David Sloan Wilson
Interferon-α (IFNα) has been prescribed to effectively treat multiple myeloma (MM) and other malignancies for decades. Its use has waned in recent years, however, due to significant toxicity and a narrow therapeutic index (TI). We sought to improve IFNα’s TI by, first, attaching it to an anti-CD38 antibody, thereby directly targeting it to MM cells, and, second, by introducing an attenuating mutation into the IFNα portion of the fusion protein rendering it relatively inactive on normal, CD38 negative cells. This anti-CD38-IFNα(attenuated) immunocytokine, or CD38-Attenukine™, exhibits 10,000-fold increased specificity for CD38 positive cells in vitro compared to native IFNα and, significantly, is ~6,000-fold less toxic to normal bone marrow cells in vitro than native IFNα. Moreover, the attenuating mutation significantly decreases IFNα biomarker activity in cynomolgus macaques indicating that this approach may yield a better safety profile in humans than native IFNα or a non-attenuated IFNα immunocytokine. In human xenograft MM tumor models, anti-CD38-IFNα(attenuated) exerts potent anti-tumor activity in mice, inducing complete tumor regression in most cases. Furthermore, anti-CD38-IFNα(attenuated) is more efficacious than standard MM treatments (lenalidomide, bortezomib, dexamethasone) and exhibits strong synergy with lenalidomide and with bortezomib in xenograft models. Our findings suggest that tumor-targeted attenuated cytokines such as IFNα can promote robust tumor killing while minimizing systemic toxicity.
Archive | 1999
Peter Wagner; Steffen Nock; Dana Ault-Riche; Christian Itin
Analytical Biochemistry | 2003
Paul Peluso; David S. Wilson; Duc Do; Huu Tran; Maanasa Venkatasubbaiah; David Quincy; Bettina Heidecker; Kelli Poindexter; Neil Tolani; Michael Phelan; Krista Witte; Linda S Jung; Peter Wagner; Steffen Nock
Archive | 2001
Paul Jedrzejewski; Steffen Nock; Peter Wagner; Pierre F. Indermuhle; Frank Zaugg
Angewandte Chemie | 2003
David S. Wilson; Steffen Nock
Archive | 1999
Peter Wagner; Dana Ault-Riche; Steffen Nock; Christian Itin